The NM_000152.5:c.655G>A variant i GAA is a missense variant that is predicted to result in the substitution of glycine by arginine at amino acid 219 (p.Gly219Arg). Over 20 individuals have been reported with this variant, at least 8 with GAA activity <10% normal in lymphocytes/leukocytes/muscle samples/<30% normal in cultured fibroblasts/ in the affected range in a clinically validated dried blood spot assay (PMIDs 11738358, 20033296, 23266370, 23601496, 24844452, 25037089, 25139343, 29124014) (PP4_Moderate). At least 12 individuals are compound heterozygous for the variant and another variant in GAA that has been classified by the ClinGen LD VCEP as as pathogenic for Pompe disease, phase unknown, including c.-32-13T>G (PMID: 21550241, 21753173, 24844452, 27711114, 30155607, 30564623; multiple individuals, max 2 x 0.5 points), c.169C>T (p.Gln57Ter) (PMID 29124014; 0.5 points), or c.2560C>T (p.Arg854Ter)(PMID 23266370; 0.5 points). At least 3 individuals are homozygous for the variant (PMID: 23787031, 25139343, 29289479, 30023291; max 2 x 0.5 points point). Total 3 points (PM3_Strong). Further individuals are compound heterozygous for the variant and either c.1735G>A (p.Glu579Lys) (PMIDs 23601496, 31193175), c.546G>A (PMID 25037089), c.784G>A (p.Glu262Lys) (PMID 11738358), c.923A>C (p.His308Pro) (PMID: 14695532), c.1796C>A (p.Ser599Tyr) (PMID: 18429042) or p.Trp376CysfsTer15 (PMID: 20033296). The allelic data for these patients will be used in the assessment of those respective variants and was not included here in order to avoid a circular logic. The highest population minor allele frequency in gnomAD v4.1.0. is 0.00004006 (3/74892 alleles) in the African/African American population, which is lower than the ClinGen LD VCEP threshold (<0.001) for PM2_Supporting, meeting this criterion (PM2_Supporting). When expressed in COS cells, this variant results in <2% wild type GAA activity and it is abnormally processed (PMIDs 14695532; 19862843) (PS3_Moderate). The computational predictor REVEL gives a score of 0.872 which is above the threshold of 0.7, evidence that correlates with impact to GAA function (PP3). There is a ClinVar entry for this variant (Variation ID 189065). In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 2.0.0): PM3_Strong, PS3_Moderate, PP4, Moderate, PP3, PM2_Supporting. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on Sept. 9, 2025).